Angiex Names Iain Dukes as Executive Chairman

27 February 2020

Angiex, Inc., a developer of innovative therapies for the treatment of solid cancers and creator of a new drug class, Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs), has named Iain Dukes, MA, D.Phil., as Executive Chairman.

Dr. Dukes brings to the company over 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, biotech company leadership from early to commercial stages, and venture capital investment.

Dr. Dukes is a Venture Partner at OrbiMed Advisors. In support of Orbimed investments, he serves as CEO of Viriom Inc., CEO of Theseus Pharmaceuticals, President of Kartos Therapeutics Ltd., Chairman of the Board of KaNDY Therapeutics Ltd., Chairman of the Board of Iovance Biotherapeutics Inc., and board member at ENYO Pharma, NeRRe Therapeutics Ltd., Kyn Therapeutics Inc., and ReViral Ltd.

Earlier, Dr. Dukes was SVP Business Development & Licensing and member of the investment committee at Merck, 2013-2016; VP External R&D at Amgen 2010-2013; and VP Scientific and Technology Licensing at GlaxoSmithKline 2000-2007.

Dr. Dukes’s educational background includes a Bsc, Phamacology (Univ. of Bath), a MSc, Cardiovascular Studies (Univ. of Leeds), a DPhil, Physiology and Pharmacology (Univ. of Oxford), and a MA, Jurisprudence/Law (Univ. of Oxford).

“I am delighted to welcome Dr. Iain Dukes to the Board of Directors and executive team at Angiex,” said Paul Jaminet, Ph.D., founder, President and COO of Angiex. “Iain is an exceptional biotech leader with a record of translating outstanding science into successful drugs and successful companies. Iain’s drug development experience will help bring Angiex’s lead drug, AGX-101, a transformative therapy for the most malignant solid cancers, into clinical trials. Iain’s business development experience will help Angiex build strategic partnerships based on our Nuclear Delivery Platform™ technologies to foster new drugs for oncology, ophthalmology, and other diseases. We couldn’t be more pleased to have Iain on our executive team.”

“Angiex is an exciting young company. Angiex’s lead drug, AGX-101, has shown remarkable efficacy and therapeutic margin in preclinical studies in mice and monkeys, and Angiex’s Nuclear Delivery Platform™ technologies have potential to generate multiple game-changing drugs,” said Dr. Dukes. “I’m excited to be part of the Angiex team.”

About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...